The Burden of Chronic Low Back Pain
Avalon Pharma (United States) · Zen-Noh (Japan)
Abstract
To examine the comorbidities, treatment patterns, health care resource utilization, and direct medical costs of patients with chronic low back pain (CLBP) in clinical practice. SUMMARY OF BACKGROUND DATA: Although the socioeconomic impact of CLBP is substantial, characterization of comorbidities, pain-related pharmacotherapy, and health care resource use/costs of patients with CLBP relative to non-CLBP controls have been infrequently documented.
Using the LifeLink Health Plan Claims Database (IMS Health Inc., Watertown, MA), patients with CLBP, defined using the International Classification of Diseases, Ninth Revision, Clinical Modification, were identified and matched (age, sex, and region) with non-CLBP individuals. Comorbidities, pain-related pharmacotherapy, and health care service use/costs (pharmacy, outpatient, inpatient, total) were compared for the 2 groups during 2008.
Citation impact
- FWCI
- 22.04
- Percentile
- 100%
- References
- 48
Authors
5- MGMugdha GoreCorresponding
Avalon Pharma (United States)
- ASAlesia Sadosky
Zen-Noh (Japan)
- BRBrett R. Stacey
- KTKei-Sing Tai
Avalon Pharma (United States)
- DLDouglas Leslie
Topics & keywords
- Medicine
- Pharmacotherapy
- Comorbidity
- Fibromyalgia
- Physical therapy
- Pharmacy
- Low back pain
- Chronic pain